Kay A B
Eur J Respir Dis Suppl. 1983;129:1-44.
The events which lead to airway narrowing in bronchial asthma are complex. There is little doubt that mast cell-derived pharmacological agents are involved, at least in part, in the initiation of the asthmatic response. However, the inflammatory response which follows mast cell activation might have more relevance to the daily pattern of asthma than the direct effects of mediators on bronchial tissue. Although the IgE mediated release of mediators from sensitized mast cells seems to play a role in pathogenesis in some individuals for some of the time, there is now increasing awareness that mast cells are also triggered by a number of non-immunological stimuli such as exercise/cold air, infection and agents which activate the complement system. Mast cell mediators are either pre-formed within granules or generated from membrane-bound phospholipids. The pre-formed mediators include histamine, various chemotactic peptides including ECF-A and the high molecular weight neutrophil chemotactic factor (NCF), proteases, glycosidases, and the heparin proteoglycan. The membrane-derived agents include the lipoxygenase products (e.g. LTB4 and the "SRS-A" leukotrienes-LTC4/D4/E4), prostaglandins and thromboxane in addition to the PAF-ace-tether (AGEPC). The mediators are diverse both in chemical composition and modes of actions. However, many of the pathological features of bronchial asthma can be explained on the basis of their recognised actions. These can be summarised as follows. Bronchial smooth muscle constriction (histamine, LTC4, LTD4, LTE4, PGF2 alfa, PGD2 and PAF); mucosal oedema (increased permeability--histamine, LTC4, LTD4 and PAF; vasodilation--PGD2, PGE2); mucous plugging (histamine, mono-HETEs and LTC4); inflammatory cell infiltrate (NCF, ECF-A peptides, HETEs, LTB4 and PAF); desquamation of epithelium (proteases, glycosidases, together with lysosomal enzymes, and basic proteins derived from neutrophils and eosinophils). It is likely that mild, easily reversible, episodic asthma is due largely to bronchial smooth muscle contraction whereas the late sustained response is more indicative of an inflammatory response, and dependent on the infiltration of neutrophils and eosinophils as the result of mediators which recruit and activate leucocytes. Much of the evidence for this is based on the demonstration that NCF concentrations in the serum are elevated during early and late phase, antigen- and exercise-induced asthma. Moderate to severe asthma is likely to be largely dependent on a subacute/chronic inflammation of the bronchi with eosinophils and mononuclear cells being prominent.(ABSTRACT TRUNCATED AT 400 WORDS)
导致支气管哮喘气道狭窄的机制很复杂。毫无疑问,肥大细胞衍生的药理介质至少在一定程度上参与了哮喘反应的起始过程。然而,肥大细胞激活后的炎症反应可能比介质对支气管组织的直接作用与哮喘的日常发作模式更相关。虽然IgE介导的致敏肥大细胞释放介质在某些个体的某些时间似乎在发病机制中起作用,但现在越来越意识到肥大细胞也可由多种非免疫刺激触发,如运动/冷空气、感染以及激活补体系统的物质。肥大细胞介质要么预先形成于颗粒内,要么由膜结合磷脂生成。预先形成的介质包括组胺、各种趋化肽,如嗜酸性粒细胞趋化因子A(ECF-A)和高分子量中性粒细胞趋化因子(NCF)、蛋白酶、糖苷酶以及肝素蛋白聚糖。膜衍生介质包括脂氧合酶产物(如白三烯B4(LTB4)和“慢反应物质-A”白三烯-LTC4/D4/E4)、前列腺素、血栓素以及血小板活化因子乙酰醚(AGEPC)。这些介质在化学成分和作用方式上各不相同。然而,支气管哮喘的许多病理特征可根据其已知作用来解释。可总结如下。支气管平滑肌收缩(组胺、LTC4、LTD4、LTE4、前列腺素F2α、前列腺素D2和血小板活化因子);粘膜水肿(通透性增加——组胺、LTC4、LTD4和血小板活化因子;血管舒张——前列腺素D2、前列腺素E2);粘液阻塞(组胺、单羟基二十碳四烯酸和LTC4);炎症细胞浸润(NCF、ECF-A肽、羟基二十碳四烯酸、LTB4和血小板活化因子);上皮细胞脱落(蛋白酶、糖苷酶,以及溶酶体酶,还有源自中性粒细胞和嗜酸性粒细胞的碱性蛋白)。轻度、易于逆转的发作性哮喘很可能主要是由于支气管平滑肌收缩,而后期持续反应更表明是一种炎症反应,并且取决于作为募集和激活白细胞的介质作用结果的中性粒细胞和嗜酸性粒细胞的浸润。对此的许多证据基于以下证明:在早期和晚期、抗原和运动诱发的哮喘期间,血清中NCF浓度升高。中度至重度哮喘很可能在很大程度上取决于支气管的亚急性/慢性炎症,其中嗜酸性粒细胞和单核细胞较为突出。(摘要截选至400字)
Eur J Respir Dis Suppl. 1983
Ann Allergy. 1988-5
Allergol Immunopathol (Madr). 1988
Boll Ist Sieroter Milan. 1988
Acta Physiol Scand Suppl. 1999-4
Rev Pneumol Clin. 1997
Ann Biol Clin (Paris). 1989
Immunol Invest. 1988
J Clin Med. 2019-9-2
Mol Med Rep. 2018-6-13
Front Pharmacol. 2013-2-1
Mutat Res. 2009-9-19